Parkman Healthcare Partners’s 4D Molecular Therapeutics FDMT Stock Holding History

Parkman Healthcare Partners’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.6M	Buy	948,184 +425,607	+81%	+$4.15M	1.29%	31
2026 Q1	$4.87M	Buy	522,577 +19,146	+4%	+$167K	0.5%	57
2025 Q4	$3.78M	Buy	503,431 +303,431	+152%	+$3.08M	0.36%	73
2025 Q3	$1.74M	Buy	+200,000	New	+$1.2M	0.18%	82

Other funds holding FDMT

Jupiter Topco New York $245B AUM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Parkman Healthcare Partners's FDMT Position: Q2 2026 in Review

Parkman Healthcare Partners increased its 4D Molecular Therapeutics (FDMT) stake by 81% in Q2 2026, buying an estimated $4.15M and bringing the position to 948,184 shares worth $12.6M. The position accounts for 1.29% of the portfolio, ranked #31.

Parkman Healthcare Partners first reported a position in FDMT in Q3 2025 and has held it in 4 quarters since. 157 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

Parkman Healthcare Partners held 948,184 shares of 4D Molecular Therapeutics worth $12.6M as of Q2 2026.
Parkman Healthcare Partners bought 425,607 4D Molecular Therapeutics shares in Q2 2026, an estimated $4.15M.
4D Molecular Therapeutics made up 1.29% of Parkman Healthcare Partners's portfolio in Q2 2026, its #31 holding.
Parkman Healthcare Partners first reported a position in 4D Molecular Therapeutics in Q3 2025 and has held it in 4 quarters since.
157 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Parkman Healthcare Partners's 13F filing for Q2 2026, filed 14 Aug 2026.